Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 159.91
ZLTQ's Cash to Debt is ranked higher than
70% of the 315 Companies
in the Global Medical Devices industry.

( Industry Median: 2.75 vs. ZLTQ: 159.91 )
Ranked among companies with meaningful Cash to Debt only.
ZLTQ' s Cash to Debt Range Over the Past 10 Years
Min: 6.45  Med: 9999.00 Max: No Debt
Current: 159.91
Equity to Asset 0.60
ZLTQ's Equity to Asset is ranked lower than
58% of the 293 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. ZLTQ: 0.60 )
Ranked among companies with meaningful Equity to Asset only.
ZLTQ' s Equity to Asset Range Over the Past 10 Years
Min: -5.35  Med: 0.71 Max: 0.89
Current: 0.6
-5.35
0.89
F-Score: 7
Z-Score: 11.40
M-Score: -2.16
WACC vs ROIC
0.95%
11.14%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 1.54
ZLTQ's Operating margin (%) is ranked lower than
51% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 2.36 vs. ZLTQ: 1.54 )
Ranked among companies with meaningful Operating margin (%) only.
ZLTQ' s Operating margin (%) Range Over the Past 10 Years
Min: -1082.23  Med: -28.38 Max: 1.22
Current: 1.54
-1082.23
1.22
Net-margin (%) 1.10
ZLTQ's Net-margin (%) is ranked lower than
51% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 1.62 vs. ZLTQ: 1.10 )
Ranked among companies with meaningful Net-margin (%) only.
ZLTQ' s Net-margin (%) Range Over the Past 10 Years
Min: -1111.78  Med: -28.43 Max: 0.88
Current: 1.1
-1111.78
0.88
ROE (%) 3.48
ZLTQ's ROE (%) is ranked higher than
52% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 2.51 vs. ZLTQ: 3.48 )
Ranked among companies with meaningful ROE (%) only.
ZLTQ' s ROE (%) Range Over the Past 10 Years
Min: -299.73  Med: -32.35 Max: 2.3
Current: 3.48
-299.73
2.3
ROA (%) 2.27
ZLTQ's ROA (%) is ranked higher than
56% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 0.42 vs. ZLTQ: 2.27 )
Ranked among companies with meaningful ROA (%) only.
ZLTQ' s ROA (%) Range Over the Past 10 Years
Min: -103.26  Med: -21.65 Max: 1.6
Current: 2.27
-103.26
1.6
ROC (Joel Greenblatt) (%) 19.95
ZLTQ's ROC (Joel Greenblatt) (%) is ranked higher than
71% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 3.95 vs. ZLTQ: 19.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ZLTQ' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1849.11  Med: -546.32 Max: 28.88
Current: 19.95
-1849.11
28.88
Revenue Growth (3Y)(%) -22.30
ZLTQ's Revenue Growth (3Y)(%) is ranked lower than
89% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. ZLTQ: -22.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ZLTQ' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -68.6  Med: -33.60 Max: -22.3
Current: -22.3
-68.6
-22.3
» ZLTQ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

ZLTQ Guru Trades in Q4 2014

Steven Cohen 1,299,930 sh (+104.49%)
Paul Tudor Jones 12,767 sh (+14.75%)
RS Investment Management 736,886 sh (-37.03%)
» More
Q1 2015

ZLTQ Guru Trades in Q1 2015

Steven Cohen 1,964,508 sh (+209.03%)
Steven Cohen 1,150,721 sh (-11.48%)
Paul Tudor Jones 8,793 sh (-31.13%)
RS Investment Management 484,116 sh (-34.30%)
» More
Q2 2015

ZLTQ Guru Trades in Q2 2015

Joel Greenblatt 15,199 sh (New)
Jim Simons 115,600 sh (New)
RS Investment Management 704,066 sh (+45.43%)
RS Investment Management 704,066 sh (+45.43%)
Steven Cohen 1,407,000 sh (+22.27%)
Paul Tudor Jones 8,800 sh (+0.08%)
» More
Q3 2015

ZLTQ Guru Trades in Q3 2015

RS Investment Management 1,242,306 sh (+76.45%)
Steven Cohen 1,441,750 sh (+2.47%)
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ZLTQ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 419.98
ZLTQ's P/E(ttm) is ranked lower than
98% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 30.18 vs. ZLTQ: 419.98 )
Ranked among companies with meaningful P/E(ttm) only.
ZLTQ' s P/E(ttm) Range Over the Past 10 Years
Min: 169.51  Med: 548.65 Max: 1567.27
Current: 419.98
169.51
1567.27
Forward P/E 39.06
ZLTQ's Forward P/E is ranked lower than
89% of the 181 Companies
in the Global Medical Devices industry.

( Industry Median: 17.92 vs. ZLTQ: 39.06 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 436.80
ZLTQ's PE(NRI) is ranked lower than
97% of the 196 Companies
in the Global Medical Devices industry.

( Industry Median: 28.80 vs. ZLTQ: 436.80 )
Ranked among companies with meaningful PE(NRI) only.
ZLTQ' s PE(NRI) Range Over the Past 10 Years
Min: 171.63  Med: 570.60 Max: 1724
Current: 436.8
171.63
1724
P/B 10.74
ZLTQ's P/B is ranked lower than
99.99% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 2.58 vs. ZLTQ: 10.74 )
Ranked among companies with meaningful P/B only.
ZLTQ' s P/B Range Over the Past 10 Years
Min: 1.79  Med: 9.80 Max: 19.19
Current: 10.74
1.79
19.19
P/S 3.92
ZLTQ's P/S is ranked lower than
81% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 2.33 vs. ZLTQ: 3.92 )
Ranked among companies with meaningful P/S only.
ZLTQ' s P/S Range Over the Past 10 Years
Min: 0.17  Med: 4.39 Max: 7.96
Current: 3.92
0.17
7.96
PFCF 136.49
ZLTQ's PFCF is ranked lower than
92% of the 199 Companies
in the Global Medical Devices industry.

( Industry Median: 33.16 vs. ZLTQ: 136.49 )
Ranked among companies with meaningful PFCF only.
ZLTQ' s PFCF Range Over the Past 10 Years
Min: 81.09  Med: 174.31 Max: 232.69
Current: 136.49
81.09
232.69
POCF 91.05
ZLTQ's POCF is ranked lower than
95% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 21.39 vs. ZLTQ: 91.05 )
Ranked among companies with meaningful POCF only.
ZLTQ' s POCF Range Over the Past 10 Years
Min: 68.93  Med: 123.67 Max: 155.13
Current: 91.05
68.93
155.13
EV-to-EBIT 230.16
ZLTQ's EV-to-EBIT is ranked lower than
98% of the 267 Companies
in the Global Medical Devices industry.

( Industry Median: 22.96 vs. ZLTQ: 230.16 )
Ranked among companies with meaningful EV-to-EBIT only.
ZLTQ' s EV-to-EBIT Range Over the Past 10 Years
Min: -231.8  Med: -5.45 Max: 655
Current: 230.16
-231.8
655
EV-to-EBITDA 141.73
ZLTQ's EV-to-EBITDA is ranked lower than
97% of the 286 Companies
in the Global Medical Devices industry.

( Industry Median: 16.67 vs. ZLTQ: 141.73 )
Ranked among companies with meaningful EV-to-EBITDA only.
ZLTQ' s EV-to-EBITDA Range Over the Past 10 Years
Min: -372.2  Med: -5.75 Max: 352.4
Current: 141.73
-372.2
352.4
Current Ratio 2.28
ZLTQ's Current Ratio is ranked lower than
57% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 2.82 vs. ZLTQ: 2.28 )
Ranked among companies with meaningful Current Ratio only.
ZLTQ' s Current Ratio Range Over the Past 10 Years
Min: 1.09  Med: 2.81 Max: 8.23
Current: 2.28
1.09
8.23
Quick Ratio 1.72
ZLTQ's Quick Ratio is ranked lower than
57% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 2.04 vs. ZLTQ: 1.72 )
Ranked among companies with meaningful Quick Ratio only.
ZLTQ' s Quick Ratio Range Over the Past 10 Years
Min: 0.78  Med: 2.31 Max: 7.85
Current: 1.72
0.78
7.85
Days Inventory 113.16
ZLTQ's Days Inventory is ranked higher than
60% of the 280 Companies
in the Global Medical Devices industry.

( Industry Median: 136.13 vs. ZLTQ: 113.16 )
Ranked among companies with meaningful Days Inventory only.
ZLTQ' s Days Inventory Range Over the Past 10 Years
Min: 46.43  Med: 87.28 Max: 109.81
Current: 113.16
46.43
109.81
Days Sales Outstanding 52.69
ZLTQ's Days Sales Outstanding is ranked higher than
74% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 69.24 vs. ZLTQ: 52.69 )
Ranked among companies with meaningful Days Sales Outstanding only.
ZLTQ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 8.79  Med: 33.80 Max: 237.12
Current: 52.69
8.79
237.12
Days Payable 70.04
ZLTQ's Days Payable is ranked higher than
56% of the 255 Companies
in the Global Medical Devices industry.

( Industry Median: 60.71 vs. ZLTQ: 70.04 )
Ranked among companies with meaningful Days Payable only.
ZLTQ' s Days Payable Range Over the Past 10 Years
Min: 42.46  Med: 64.00 Max: 144.83
Current: 70.04
42.46
144.83

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 13.16
ZLTQ's Price/Net Current Asset Value is ranked lower than
73% of the 293 Companies
in the Global Medical Devices industry.

( Industry Median: 6.17 vs. ZLTQ: 13.16 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ZLTQ' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.79  Med: 9.90 Max: 21.26
Current: 13.16
2.79
21.26
Price/Tangible Book 11.56
ZLTQ's Price/Tangible Book is ranked lower than
82% of the 378 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. ZLTQ: 11.56 )
Ranked among companies with meaningful Price/Tangible Book only.
ZLTQ' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.32  Med: 8.08 Max: 18.68
Current: 11.56
2.32
18.68
Price/Median PS Value 0.89
ZLTQ's Price/Median PS Value is ranked higher than
62% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 1.00 vs. ZLTQ: 0.89 )
Ranked among companies with meaningful Price/Median PS Value only.
ZLTQ' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.05  Med: 0.85 Max: 1.46
Current: 0.89
0.05
1.46
Price/Graham Number 13.16
ZLTQ's Price/Graham Number is ranked lower than
95% of the 229 Companies
in the Global Medical Devices industry.

( Industry Median: 3.38 vs. ZLTQ: 13.16 )
Ranked among companies with meaningful Price/Graham Number only.
ZLTQ' s Price/Graham Number Range Over the Past 10 Years
Min: 12.09  Med: 16.06 Max: 22.69
Current: 13.16
12.09
22.69
Earnings Yield (Greenblatt) (%) 0.41
ZLTQ's Earnings Yield (Greenblatt) (%) is ranked lower than
52% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. ZLTQ: 0.41 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ZLTQ' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 0.30 Max: 0.8
Current: 0.41
0.2
0.8

More Statistics

Revenue(Mil) $228
EPS $ 0.05
Beta0.43
Short Percentage of Float29.06%
52-Week Range $21.51 - 38.49
Shares Outstanding(Mil)39.03

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 255 315 359 399
EPS($) 0.09 0.31 0.56 0.81
EPS without NRI($) 0.09 0.31 0.56 0.81

Latest Earnings Webcast

Call starts at Oct 27, 2015 04:30 PM EDT

» More Conference Calls

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
ZELTIQ Aesthetics Inc was incorporated in the state of Delaware on March 22, 2005. In August 2011, the Company incorporated ZELTIQ Limited as a wholly-owned subsidiary in the United Kingdom to serve as its sales office for direct sales in Europe. The Company was founded to develop and commercialize a non-invasive product for the selective reduction of fat. On October 24, 2011, the Company completed its initial public offering, or IPO, of 8,050,000 shares of common stock, of which 7,743,000 shares were sold by the Company and 307,000 shares were sold by existing stockholders. The Company generates revenue from sales of CoolSculpting system and from sales of consumables to its customers. Its geographical region includes North America and International. The Company's first commercial product, the CoolSculpting system, is designed to selectively reduce stubborn fat bulges. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. The Company manufactures and distributes its CoolSculpting system, including procedure packs, at its Dublin facility. The Livermore facility is used primarily for raw material storage. Through 2012 and the beginning of 2013, the Company has utilized OnCore Manufacturing LLC to manufacture and supply CoolSculpting system. ZELTIQ, CoolSculpting, and Company's logo are registered trademarks in the United States and in certain foreign countries. The design, development, manufacture, testing and sale of products are subject to regulation by governmental authorities, mainly FDA, and corresponding state and foreign regulatory agencies.
» More Articles for ZLTQ

Headlines

Articles On GuruFocus.com
Steven Cohen's Newest Buys, Additions and Reductions Mar 04 2015 
Steven Cohen Buys New Drug Stock, Triples Investment in Medical Company Jan 25 2015 
4 Stocks To Buy, 1 To Avoid In 2012 Feb 18 2012 
Weekly CFO Sales Highlight: INFA, DHR, AN, SMTC, ZLTQ Oct 31 2011 

More From Other Websites
Medical Appliances & Equipment Equities Ahead of Market -- ResMed, ZELTIQ Aesthetics, MiMedx Group,... Feb 03 2016
ZELTIQ to Present at the Leerink Partners 5th Annual Global Healthcare Conference Jan 28 2016
ZELTIQ to Present at the Leerink Partners 5th Annual Global Healthcare Conference Jan 28 2016
ZELTIQ Added to the S&P SmallCap 600(R) Index Jan 27 2016
ZELTIQ Added to the S&P SmallCap 600(R) Index Jan 27 2016
Citizens Financial Group Set to Join the S&P 500; ZELTIQ Aesthetics, RE/MAX to Join S&P SmallCap 600 Jan 26 2016
ZELTIQ Aesthetics upgraded by Griffin Securities Jan 22 2016
ZELTIQ AESTHETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in... Jan 12 2016
ZELTIQ Announces Executive Leadership Addition and Global Commercial Operations Realignment Jan 12 2016
ZELTIQ Reports Preliminary Fourth Quarter and Full Year 2015 Revenue Jan 12 2016
ZELTIQ(R) Unveils National CoolSculpting(R) Ad Campaign Dec 28 2015
ZELTIQ to Present at the J.P. Morgan 34th Annual Healthcare Conference Dec 18 2015
Goldman Sachs Picks These 9 Health Care Stocks Now Dec 17 2015
ZELTIQ AESTHETICS INC Financials Dec 08 2015
Galderma and ZELTIQ Announce U.S. Collaboration in Aesthetics Dec 08 2015
Galderma and ZELTIQ Announce U.S. Collaboration in Aesthetics Dec 08 2015
Zeltiq Aesthetics Inc (ZLTQ): Are Hedge Funds Right About This Stock? Dec 02 2015
Elite Hedge Funds Make Big Moves In These 3 Healthcare Stocks Dec 01 2015
Northwest Natural Gas Co (NWN): Are Hedge Funds Right About This Stock? Nov 28 2015
Should You Avoid Cohen & Steers, Inc. (CNS)? Nov 25 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK